Welcome to our dedicated page for ResMed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on ResMed stock.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in digital health and cloud-connected medical devices, focusing on innovative solutions that treat and prevent respiratory conditions like sleep apnea and COPD. By transforming patient care, ResMed empowers individuals to live healthier, higher-quality lives. Their diverse product portfolio includes flow generators, masks, and accessories designed to keep patients out of hospitals and manage chronic diseases effectively.
Operating in over 140 countries, ResMed’s cloud-connected medical devices provide data-driven insights used by patients, healthcare providers, and payers to deliver personalized and efficient healthcare. Their comprehensive out-of-hospital software platforms support professionals and caregivers, enhancing the quality of life and reducing healthcare costs. The company earns about two-thirds of its revenue from the Americas, with the remainder coming from Europe, Japan, and Australia.
In recent developments, ResMed successfully defended its intellectual property against a patent infringement claim by NYU, with the PTAB ruling in favor of ResMed on all challenged claims. This outcome underscores the company’s commitment to innovation, backed by over 9,500 issued or pending patents and designs.
ResMed also made headlines with a global field action to update guides for masks with magnets, ensuring user safety around medical implants. Their proactive approach and dedication to patient safety were evident as they addressed potential magnetic interference issues without necessitating a product recall.
Financially, ResMed continues to demonstrate strong growth. In the second quarter of fiscal year 2024, the company reported double-digit growth across its devices, masks, accessories, and residential care software businesses. This robust performance highlights ResMed’s strategic focus on expanding its product offerings and maintaining cost discipline.
ResMed's latest product launch, the AirCurve 11 series, further showcases their commitment to innovation. These bilevel PAP devices feature advanced digital technology to improve patient comfort and compliance, addressing challenges in CPAP therapy adaptation.
Continuing its leadership in respiratory care, ResMed actively participates in significant industry conferences such as the American Thoracic Society International Conference and SLEEP 2024, presenting crucial research on sleep disorders and their impact on health. This research supports the effectiveness of PAP therapy in reducing mortality and improving patient outcomes, solidifying ResMed’s role as a pioneer in the field.
With a clear focus on enhancing patient care through technology and innovation, ResMed is well-positioned to lead the expansion of sleep and respiratory health.
ResMed (NYSE: RMD) announces that Rob Douglas, president and COO, will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 1:20 p.m. EDT. The presentation will be accessible via a live webcast, with a replay available for viewing through June 13, 2022. ResMed specializes in developing innovative solutions for chronic diseases like sleep apnea and COPD, focusing on digital health technologies and cloud-connected medical devices that enhance patient care and reduce healthcare costs globally.
ResMed (NYSE: RMD) announces that CEO Mick Farrell will participate in a virtual fireside chat at the Citi Healthcare Conference on February 23, 2022, at 12:30 p.m. EST. This event will be accessible via webcast, with a replay available for 24 hours post-event until February 23, 2023. ResMed specializes in innovative solutions for chronic diseases, particularly focusing on digital health technologies and cloud-connected medical devices aimed at enhancing patient care and reducing healthcare costs globally.
ResMed has appointed Urvashi Tyagi as its new Chief Technology Officer effective February 1, 2022. With over 25 years of experience from companies like ADP, American Express, and Amazon, Tyagi will spearhead ResMed's digital health innovation and cloud technologies. Bobby Ghoshal, the former CTO, will now focus entirely on leading the company’s SaaS business. CEO Mick Farrell emphasized Tyagi's leadership skills and experience as pivotal for enhancing ResMed's digital ecosystem aimed at improving the lives of 250 million people by 2025.
ResMed (NYSE: RMD) reported a 12% year-over-year revenue increase, reaching $894.9 million for Q2 2022. Operating profit also rose by 12%, while non-GAAP operating profit saw a 5% growth. Diluted earnings per share climbed to $1.37, and non-GAAP diluted earnings per share hit $1.47. Despite challenges in supply chains, ResMed managed to meet high demand for sleep and respiratory care products. The company announces a quarterly cash dividend of $0.42 per share, payable on March 17, 2022, and continues its goal to improve life quality for 250 million people by 2025.
ResMed (NYSE: RMD) announced it will release its financial and operational results for Q2 fiscal year 2022 on January 27, 2022, post-market. This will be followed by a management webcast to discuss the results and other relevant information. Key details include the earnings call scheduled at 1:30 p.m. PST / 4:30 p.m. EST, with international times listed for London and Sydney. A replay of the webcast will be available approximately two hours after the event.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. EST via webcast. This conference offers an opportunity for investors to hear about ResMed’s innovative solutions for chronic diseases and its digital health technologies. Access to the live webcast and the replay will be available through their investor relations website. The presentation aims to highlight how ResMed is improving healthcare quality and reducing costs globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022, at 4:00 p.m. EST. The event will be available via live webcast, with a replay accessible for one year after the event. ResMed focuses on innovative healthcare solutions that treat chronic diseases, enhancing quality of life and reducing healthcare costs across more than 140 countries.
ResMed has appointed Desney Tan and John Hernandez to its board of directors, increasing the board from eight to ten members. Tan, current vice president at Microsoft, brings expertise in AI and health R&D, while Hernandez leads clinical research at Google. Their backgrounds in digital health aim to enhance ResMed's strategy of improving 250 million lives by 2025. This strategic move is part of ResMed's commitment to advancements in digital health and health economics.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on November 10, 2021, at approximately 1:00 p.m. EST. The event will be accessible via video webcast, with a replay available 24 hours post-event until February 8, 2021. ResMed focuses on innovative healthcare solutions, particularly in digital health technologies and cloud-connected medical devices for chronic diseases.
FAQ
What is the current stock price of ResMed (RMD)?
What is the market cap of ResMed (RMD)?
What does ResMed Inc. specialize in?
Where does ResMed operate?
What are some of ResMed’s recent key developments?
How does ResMed ensure patient safety with its products?
What financial performance did ResMed report recently?
What innovations has ResMed introduced recently?
How does ResMed contribute to healthcare research?
What is ResMed’s approach to out-of-hospital care?
What kind of products does ResMed develop?
How does ResMed support its innovation?
